Pharmacokinetics and biodistribution of genetically engineered antibodies
β Scribed by Surinder K Batra; Maneesh Jain; Uwe A Wittel; Subhash C Chauhan; David Colcher
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 70 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0958-1669
No coin nor oath required. For personal study only.
β¦ Synopsis
The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.
π SIMILAR VOLUMES
## Abstract Recently, wellβordered biological materials have been exploited to pattern inorganic nanoparticles into linear arrays that are of particular interest for nanoelectronic applications. In this work, a de novo designed __E. coli__βexpressed polypeptide (previously shown to form highly rect
## Abstract __Salmonella typhimurium__ harbours a Auβresistance system whose expression is controlled by GolS, a transcriptional regulator of the MerR family that selectively detects Au with high sensitivity. We developed both __Salmonella__ and genetically engineered __Escherichia coli__ strains a